Sitagliptin Phosphate Monohydrate IP 100mg., Dapagliflozin Propanediol Monohydrate 10mg.
DESIGN CONTROLS > PREVENTS > OBJECTIVE self-nanoemulsifying drug delivery systems (SNEDDS) MANAGEMENT OF TYPE -2 DIABETES
ADD ON TREATMENT:
Dapagliflozin and Sitagliptin had comparable effects on improving insulin resistant and blood glucose control, and these benefits may be associated with improvement of systemic inflammation.
Dapagliflozin increases urinary glucose excretion and reduces blood glucose levels.
Sitagliptin reduces the amount of glucose produced by the liver by raising insulin levels and decreasing the levels of glucagon
COMPARABLE BENEFITS:
Treatment with dapagliflozin provides additional clinical benefit and is well tolerated.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Comparable effects on improving insulin resistant and blood glucose control
Lowers blood pressure due to its natriuresis effect.
Reduces oxidative stress and may delay atherosclerosis